Atrayee Bhattacharya

640 total citations
33 papers, 444 citations indexed

About

Atrayee Bhattacharya is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Atrayee Bhattacharya has authored 33 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Atrayee Bhattacharya's work include RNA modifications and cancer (12 papers), Glycosylation and Glycoproteins Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Atrayee Bhattacharya is often cited by papers focused on RNA modifications and cancer (12 papers), Glycosylation and Glycoproteins Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Atrayee Bhattacharya collaborates with scholars based in United States, Japan and China. Atrayee Bhattacharya's co-authors include Donald Küfe, Nami Yamashita, Atsushi Fushimi, Masayuki Hagiwara, Mark D. Long, Song Liu, Yoshihiro Morimoto, Yota Yasumizu, Hasan Rajabi and Mototsugu Oya and has published in prestigious journals such as Cancer Research, Oncogene and The FASEB Journal.

In The Last Decade

Atrayee Bhattacharya

26 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atrayee Bhattacharya United States 13 310 159 98 91 73 33 444
Weilong Chen China 9 246 0.8× 197 1.2× 118 1.2× 53 0.6× 127 1.7× 14 436
Eva Y‐HP Lee United States 5 283 0.9× 128 0.8× 121 1.2× 50 0.5× 58 0.8× 6 409
Ranran Kong China 14 331 1.1× 107 0.7× 189 1.9× 67 0.7× 51 0.7× 37 445
Shengliang Qiu China 9 136 0.4× 169 1.1× 65 0.7× 78 0.9× 74 1.0× 17 327
Chandrika Jeyamohan United States 6 224 0.7× 89 0.6× 145 1.5× 52 0.6× 35 0.5× 9 358
Shi-Rong Zhang China 9 221 0.7× 227 1.4× 150 1.5× 78 0.9× 71 1.0× 11 441
Da-Li Tian China 11 310 1.0× 128 0.8× 198 2.0× 50 0.5× 25 0.3× 24 447
Meisongzhu Yang China 12 386 1.2× 104 0.7× 220 2.2× 114 1.3× 63 0.9× 16 524
Jin-Zhi Xu China 9 205 0.7× 225 1.4× 152 1.6× 72 0.8× 70 1.0× 10 426
Jie Yao China 14 212 0.7× 92 0.6× 120 1.2× 168 1.8× 58 0.8× 51 488

Countries citing papers authored by Atrayee Bhattacharya

Since Specialization
Citations

This map shows the geographic impact of Atrayee Bhattacharya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atrayee Bhattacharya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atrayee Bhattacharya more than expected).

Fields of papers citing papers by Atrayee Bhattacharya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atrayee Bhattacharya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atrayee Bhattacharya. The network helps show where Atrayee Bhattacharya may publish in the future.

Co-authorship network of co-authors of Atrayee Bhattacharya

This figure shows the co-authorship network connecting the top 25 collaborators of Atrayee Bhattacharya. A scholar is included among the top collaborators of Atrayee Bhattacharya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atrayee Bhattacharya. Atrayee Bhattacharya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shigeta, Keisuke, Hiroshi Hongo, Sheng‐Yu Ku, et al.. (2025). MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy. JCI Insight. 10(14). 1 indexed citations
2.
Takamori, Shinkichi, Hideko Isozaki, Keisuke Shigeta, et al.. (2025). Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells. Cell Death Discovery. 11(1). 372–372.
3.
Takamori, Shinkichi, Atrayee Bhattacharya, Chie Kikutake, et al.. (2025). MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer. Signal Transduction and Targeted Therapy. 10(1). 389–389.
4.
Haratake, Naoki, Atrayee Bhattacharya, Weipu Mao, et al.. (2024). IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS. Cancer Research Communications. 4(5). 1268–1281. 4 indexed citations
5.
Mao, Weipu, Kangjie Xu, Jiang Geng, et al.. (2024). Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. iScience. 27(10). 110921–110921.
6.
Bhattacharya, Atrayee, Chi Ngai Chan, Atsushi Fushimi, et al.. (2024). MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression. Oncogene. 43(28). 2199–2214. 9 indexed citations
7.
Ozawa, Hiroki, Naoki Haratake, Atrayee Bhattacharya, et al.. (2024). MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer. Biomedicines. 12(7). 1509–1509.
8.
Haratake, Naoki, et al.. (2024). Abstract 3279: MUC1 is necessary for the inflammatory memory response to osimertinib resistance in NSCLC cells. Cancer Research. 84(6_Supplement). 3279–3279.
9.
Bhattacharya, Atrayee, Atsushi Fushimi, Keyi Wang, et al.. (2023). MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression. Communications Biology. 6(1). 1030–1030. 13 indexed citations
10.
Haratake, Naoki, Hiroki Ozawa, Yoshihiro Morimoto, et al.. (2023). Abstract B089: MUC1-C is a common driver of acquired osimertinb resistance in NSCLC. Molecular Cancer Therapeutics. 22(12_Supplement). B089–B089. 2 indexed citations
11.
Morimoto, Yoshihiro, Nami Yamashita, Naoki Haratake, et al.. (2023). MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells. Journal for ImmunoTherapy of Cancer. 11(2). e006238–e006238. 16 indexed citations
12.
Haratake, Naoki, Hiroki Ozawa, Yoshihiro Morimoto, et al.. (2023). MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC. Journal of Thoracic Oncology. 19(3). 434–450. 24 indexed citations
13.
Yamashita, Nami, Henry Withers, Yoshihiro Morimoto, et al.. (2023). MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells. iScience. 26(11). 108168–108168. 7 indexed citations
14.
Yamashita, Nami, Yoshihiro Morimoto, Atsushi Fushimi, et al.. (2022). MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Molecular Cancer Research. 21(3). 274–289. 25 indexed citations
15.
Morimoto, Yoshihiro, Atsushi Fushimi, Nami Yamashita, et al.. (2022). Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. Oncogene. 41(27). 3511–3523. 16 indexed citations
16.
Fushimi, Atsushi, Yoshihiro Morimoto, Satoshi Ishikawa, et al.. (2022). Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer. Molecular Cancer Research. 20(9). 1379–1390. 12 indexed citations
17.
Bhattacharya, Atrayee, et al.. (2022). ATAC-Seq Optimization for Cancer Epigenetics Research. Journal of Visualized Experiments. 3 indexed citations
18.
Hagiwara, Masayuki, Atsushi Fushimi, Nami Yamashita, et al.. (2021). MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene. 40(30). 4930–4940. 54 indexed citations
19.
Yamashita, Nami, Mark D. Long, Atsushi Fushimi, et al.. (2021). MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 9(1). e002115–e002115. 57 indexed citations
20.
Hagiwara, Masayuki, Yota Yasumizu, Nami Yamashita, et al.. (2020). MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Research. 81(4). 1111–1122. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weilong Chen Breakdown of academic impact, for papers by Eva Y‐HP Lee Breakdown of academic impact, for papers by Ranran Kong Breakdown of academic impact, for papers by Shengliang Qiu Breakdown of academic impact, for papers by Chandrika Jeyamohan Breakdown of academic impact, for papers by Shi-Rong Zhang Breakdown of academic impact, for papers by Da-Li Tian Breakdown of academic impact, for papers by Meisongzhu Yang Breakdown of academic impact, for papers by Jin-Zhi Xu Breakdown of academic impact, for papers by Jie Yao
Rankless by CCL
2026